Effect of Chronic Delivery of the Toll-like Receptor 4 Antagonist (+)-Naltrexone on Incubation of Heroin Craving-Reference-Cited by-同舟云学术

Effect of Chronic Delivery of the Toll-like Receptor 4 Antagonist (+)-Naltrexone on Incubation of Heroin Craving

Published:2013-04 Issue:8 Volume:73 Page:729-737
ISSN:0006-3223
Container-title:Biological Psychiatry
language:en
Short-container-title:Biological Psychiatry

Author:

Theberge Florence R.,Li Xuan,Kambhampati Sarita,Pickens Charles L.,St. Laurent Robyn,Bossert Jennifer M.,Baumann Michael H.,Hutchinson Mark R.,Rice Kenner C.,Watkins Linda R.,Shaham Yavin

Publisher

Elsevier BV

Subject

Biological Psychiatry

Reference79 articles.

1. Drug addiction and drug abuse;Jaffe,1990

2. Dynamics of drug dependence. Implications of a conditioning theory for research and treatment;Wikler;Arch Gen Psychiatry,1973

3. Classical conditioning in human opioid dependence;O'Brien,1986

4. Toward a model of drug relapse: An assessment of the validity of the reinstatement procedure;Epstein;Psychopharmacology (Berl),2006

5. Endogenous GDNF in ventral tegmental area and nucleus accumbens does not play a role in the incubation of heroin craving;Airavaara;Addict Biol,2011

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microglia contribute to methamphetamine reinforcement and reflect persistent transcriptional and morphological adaptations to the drug;Brain, Behavior, and Immunity;2024-08

2. Psilocybin reduces heroin seeking behavior and modulates inflammatory gene expression in the nucleus accumbens and prefrontal cortex of male rats;2024-06-01

3. The estrous cycle has no effect on incubation of methamphetamine craving and associated Fos expression in dorsomedial striatum and anterior intralaminar nucleus of thalamus;Addiction Neuroscience;2024-06

4. Opioid craving does not incubate over time in inpatient or outpatient treatment studies: Is the preclinical incubation of craving model lost in translation?;Neuroscience & Biobehavioral Reviews;2024-05

5. Neuroimmune modulators as novel pharmacotherapies for substance use disorders;Brain, Behavior, & Immunity - Health;2024-03